ArticleAmerican journal of cardiovascular disease2021
Proteinuria versus albuminuria in 24-hour urine collection: prevalence and clinical outcome in non-hypoxemic adult patients with congenital heart disease.
Article in American journal of cardiovascular disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Risk Factors for Chronic Kidney Disease in Adult Patients with Congenital Heart Disease and Its Relationship with Cardiovascular Mortality.Journal of clinical medicine · 2024Article
- Changes in blood biomarkers correlate with changes in cardiac size and function in patients with tetralogy of Fallot.International journal of cardiology. Congenital heart disease · 2024Article
- Crystalluria in adolescent and adult patients with congenital heart disease.World journal of urology · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital heart disease (CHD) patients, especially cyanotic ones, usually have renal function impairment. However, little information exists in non-cyanotic CHD patients. The objective of this study is to determine renal failure in non-hypoxemic CHD patients by measuring the amount of protein and albumin released in urine over a 24-hour period and determining the glomerular filtration rate (GFR). Prospective study of consecutive outpatient non-hypoxemic CHD patients followed up in a single tertiary referral hospital. Demographic, clinical, blood test and 24-hour urine collection were recorded. 264 CHD patients, 22 (18-343) years old and 160 (61%) males, were followed up during 9.2 (5.9-11.1) years. 137 (52%), 96 (36%) and 31 (18%) CHD patients had mild, moderate, and great anatomical CHD defects. 44 (17%) and 32 (12%) CHD patients showed proteinuria (≥ 150 mg/24 hours) and albuminuria (> 30 mg/24 hours) respectively. 35 out of 44 (79%) CHD patients with proteinuria (≥ 150 mg/24 hours) showed normal to mild albuminuria levels (< 30 mg/24 hours). Variables associated with proteinuria were male sex, body mass index, auricular fibrillation/flutter, arterial hypertension, diabetes mellitus and being under angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB), loop diuretics or anti-aldosterone treatment. Major adverse cardiovascular events (MACE), defined as cardiovascular and non-cardiovascular deaths, stroke, myocardial infarction and heart failure requiring hospitalization, occurred in 16 (6%) patients during the follow up time. Multivariate Cox regression analysis showed that older patients, patients with a great CHD complexity and patients with proteinuria [6.99 (1.90-24.74), P=0.003] had a significant higher risk of MACE. Proteinuria is frequent among non-hypoxemic CHD patients and occurs mostly in those with a GFR above 60 ml/min/1.73 m
Indexed as
Identifiers
33815919PMC8012297W3141664326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.